ClinicalTrials.gg
Not yet recruitingNCT07526285Updated Nov 13, 2026

Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) for Treatment of Post-Traumatic Stress Disorder (PTSD)

An interventional study of Transcranial Magnetic Stimulation and Transcranial Magnetic Stimulation Sham in Posttraumatic Stress Disorder (PTSD), sponsored by Massachusetts General Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital — 5 open to participants now, 9 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Massachusetts General Hospital.

Planned enrollment
5th of 27
100 · median 57
Started
2027
the only one that year
No phase
15 of 28
4 open now
Registered
28th of 28
by date

Among the 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital, this one is the 5th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2027, is one of 15 with no phase, and was the 28th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

5 of the 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This study is testing a personalized form of brain stimulation called PrTMS as a treatment for post-traumatic stress disorder (PTSD) in military service members and veterans. Unlike standard approaches, this treatment uses a simple brainwave test (EEG) to tailor the therapy to each individual. Participants will be randomly assigned to receive either active treatment or a comparison (sham) treatment over 6 weeks. Researchers will track changes in PTSD symptoms, mood, sleep, and overall well-being, including using wearable devices to measure things like sleep and heart rate. The goal is to see whether this personalized approach can provide greater and longer-lasting relief for individuals living with PTSD.

Read the detailed description

This study is a randomized, double-blind, sham-controlled trial evaluating a personalized approach to repetitive transcranial magnetic stimulation (PrTMS) for the treatment of post-traumatic stress disorder (PTSD) in military service members and veterans. PrTMS integrates spectral electroencephalography (sEEG) with neurocognitive assessments to individualize stimulation parameters, including frequency and intensity, and to allow for dynamic adjustment over the course of treatment based on each participant's evolving neurophysiological profile. Participants will undergo a 6-week treatment protocol (5 sessions per week), followed by longitudinal assessments over 6 months to evaluate durability of response. Multimodal outcomes will include clinician-administered and self-report measures of PTSD, mood, anxiety, and sleep, as well as physiologic and behavioral data collected via wearable devices. This study is designed to determine whether EEG-guided, precision neuromodulation improves clinical outcomes compared to standard, non-personalized stimulation approaches and to inform the development of individualized treatment strategies in PTSD.

03

Conditions studied

  • Posttraumatic Stress Disorder (PTSD)

Keywords

  • Transcranial Magnetic Stimulation
  • Posttraumatic Stress Disorder
  • Veterans
  • Precision Medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reserve or former member of the military (veteran status)
  • Age 18 years or older
  • Primary diagnosis of post-traumatic stress disorder (PTSD) confirmed by the - Clinician-Administered PTSD Scale for (CAPS-5)
  • Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) score ≥ 33, indicating PTSD symptoms
  • Proficient in English (spoken and written) to ensure understanding of study procedures and

Exclusion criteria

Exclusion Criteria:

  • History of open-skull traumatic brain injury
  • seizure disorder or history of manic episodes
  • Neurological conditions associated with increased risk (e.g., increased intracranial pressure, brain lesions, stroke, cerebral aneurysm)
  • Electroencephalogram (EEG) abnormalities suggesting elevated seizure risk
  • Repetitive transcranial magnetic stimulation (rTMS) within 3 months prior to screening
  • Current use of antipsychotic or anticonvulsant medications
  • Presence of intracranial implants or non-removable metal in or near the head (excluding the mouth)
  • Clinically significant or unstable medical conditions, including active suicidal ideation
  • Uncontrolled medical illness (e.g., thyroid, hepatic, cardiac, pulmonary, or renal disease)
  • Initiation of PTSD-specific treatment within the past 4 weeks (participants on a stable regimen may be eligible)
  • Pregnancy (for women of )
  • Any condition that, in the opinion of the investigator, may interfere with study participation or completion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Active PrTMS (EEG-Guided rTMS)

    Participants receive personalized, EEG-guided repetitive transcranial magnetic stimulation (PrTMS) administered 5 days per week for 6 weeks, with stimulation parameters individualized and adjusted over time based on serial sEEG and neurocognitive assessments.

    Device: Transcranial Magnetic Stimulation

  • Sham comparator
    Sham PrTMS

    Participants receive sham repetitive transcranial magnetic stimulation (rTMS) administered 5 days per week for 6 weeks using a sham coil that mimics the sound and sensation of active treatment without delivering a therapeutic magnetic field.

    Device: Transcranial Magnetic Stimulation Sham

Interventions

  • DeviceTranscranial Magnetic Stimulation

    Personalized repetitive transcranial magnetic stimulation (PrTMS) is delivered using the Neurocare Apollo TMS Therapy System for 30 minutes per session, 5 days per week, over 6 weeks. Stimulation parameters (frequency 8-13 Hz and intensity typically 50-60% of motor threshold) are individualized based on baseline and serial spectral EEG (sEEG) assessments, with adjustments made throughout treatment to optimize response.

  • DeviceTranscranial Magnetic Stimulation Sham

    Sham stimulation will be delivered using the same Neurocare Apollo TMS Therapy System as the active intervention, with identical treatment schedule (5 days per week for 6 weeks; 30 minutes per session). A sham coil identical in appearance to the active coil will be used, which does not generate a therapeutic magnetic field. To mimic the sensory experience of active treatment, the sham procedure will produce similar auditory clicking and will include a surface electrical stimulation (TENS) applied to the forehead to replicate scalp sensations and mild muscle contraction. This approach is designed to maintain blinding while delivering no active neuromodulatory effect.

06

What researchers measure

Primary outcomes

  1. Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

    The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a structured interview and gold standard for diagnosing and assessing PTSD in clinical and research settings. It assesses current or lifetime PTSD based on DSM-5 criteria and measures symptom severity across the 20 PTSD symptoms, including the dissociative subtype, in relation to a single index traumatic event. Total severity scores range from 0 to 80, with higher scores indicating worse PTSD symptom severity.

    Time frame: At baseline and the end of treatment at Week 6.

Secondary outcomes

  1. Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5)

    The Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) is a 20-item self-report measure that assesses PTSD symptom presence and severity across DSM-5 symptom clusters, including re-experiencing, avoidance, negative alterations in cognition and mood, and arousal. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.

    Time frame: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

  2. Generalized Anxiety Disorder-7 (GAD-7)

    The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report scale used to assess the severity of generalized anxiety symptoms and to screen for anxiety over the past two weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity.

    Time frame: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

  3. Patient Health Questionnaire-9 (PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure used to screen, diagnose, monitor, and assess the severity of depression. Total scores range from 0 to 27, with higher scores indicating greater depression severity.

    Time frame: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

  4. Tinnitus Functional Index (TFI)

    The Tinnitus Functional Index (TFI) is a 25-item self-report questionnaire designed to measure the severity, negative impact, and treatment-related changes of tinnitus on a person's daily life over the past week. Total scores range from 0 to 100, with higher scores indicating greater tinnitus severity and functional impact.

    Time frame: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

  5. TMS Tolerability Worksheet (TTW)

    The TMS Tolerability Worksheet (TTW) is a clinician-administered tool used to document session-related side effects and adverse events associated with transcranial magnetic stimulation (TMS), including symptoms such as headache, neck pain, discomfort at the stimulation site, and hearing changes, with severity categorized as none, mild, moderate, or severe.

    Time frame: At baseline and weekly during Weeks 1-6.

  6. Pittsburgh Sleep Quality Index Addendum (PSQI-A)

    The Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A) is a self-report measure that assesses disruptive nocturnal behaviors associated with PTSD, including nightmares, panic, hot flashes, and acting out dreams. Total scores range from 0 to 21, with higher scores indicating greater severity of disruptive nocturnal behaviors.

    Time frame: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

  7. Total Sleep Time (Oura Ring)

    Total sleep time, measured in hours per night using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  8. Sleep Efficiency (Oura Ring)

    Sleep efficiency, expressed as a percentage (0-100%) representing the ratio of time spent asleep relative to the total time in bed, using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  9. Sleep Latency (Oura Ring)

    Sleep latency, measured in minutes, defined as the time from the start of the sleep period to sleep onset, as recorded by the Oura Ring wearable device. Typical values range from approximately 0 to 60 minutes.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  10. REM Sleep Duration (Oura Ring)

    Duration of rapid eye movement (REM) sleep, measured in minutes using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  11. REM Sleep Percentage (Oura Ring)

    REM sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  12. Light Sleep Duration (Oura Ring)

    Duration of light sleep, measured in minutes using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  13. Light Sleep Percentage (Oura Ring)

    Light sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  14. Deep Sleep Duration (Oura Ring)

    Duration of deep (slow-wave) sleep, measured in minutes using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  15. Deep Sleep Percentage (Oura Ring)

    Deep (slow-wave) sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  16. Resting Heart Rate (Oura Ring)

    Resting heart rate, measured in beats per minute (bpm) using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  17. Heart Rate Variability (Oura Ring)

    Heart rate variability (HRV), measured in milliseconds (ms) using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  18. Body Temperature (Oura Ring)

    Nightly body temperature deviation from baseline, measured in degrees Fahrenheit (°F) using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  19. Daily Step Count (Oura Ring)

    Daily step count, measured as the number of steps per day using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  20. Active Energy Expenditure (Oura Ring)

    Active energy expenditure, measured in kilocalories per day (kcal/day) using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  21. Total Energy Expenditure (Oura Ring)

    Total energy expenditure, measured in kilocalories per day (kcal/day) using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  22. Sedentary Activity Duration (Oura Ring)

    Duration of sedentary activity, measured in minutes per day using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  23. Light Activity Duration (Oura Ring)

    Duration of light physical activity, measured in minutes per day using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  24. Moderate Activity Duration (Oura Ring)

    Duration of moderate physical activity, measured in minutes per day using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

  25. Vigorous Activity Duration (Oura Ring)

    Duration of vigorous physical activity, measured in minutes per day using the Oura Ring wearable device.

    Time frame: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

07

Study locations

1 site
  • Home Base
    Charlestown, Massachusetts 02129, United States
08

References and documents

Publications

  • Makale MT, Nybo C, Blum K, Dennen CA, Elman I, Murphy KT. Pilot Study of Personalized Transcranial Magnetic Stimulation with Spectral Electroencephalogram Analyses for Assessing and Treating Persons with Autism. J Pers Med. 2024 Aug 12;14(8):857. doi: 10.3390/jpm14080857. PubMed 39202048 ↗
  • Makale MT, Nybo C, Keifer J, Blum K, Dennen CA, Baron D, Sunder K, Elman I, Makale MR, Thanos PK, Murphy KT. Preliminary Observations of Personalized Repetitive Magnetic Stimulation (PrTMS) Guided by EEG Spectra for Concussion. Brain Sci. 2023 Aug 9;13(8):1179. doi: 10.3390/brainsci13081179. PubMed 37626535 ↗
  • Makale MT, Abbasi S, Nybo C, Keifer J, Christman L, Fairchild JK, Yesavage J, Blum K, Gold MS, Baron D, Cadet JL, Elman I, Dennen CA, Murphy KT. Personalized repetitive transcranial magnetic stimulation (prtms(R)) for post-traumatic stress disorder (ptsd) in military combat veterans. Heliyon. 2023 Aug 8;9(8):e18943. doi: 10.1016/j.heliyon.2023.e18943. eCollection 2023 Aug. PubMed 37609394 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared. Only de-identified, aggregate data may be shared with collaborators, including the United States Air Force Research Laboratory (USAFRL), under a data sharing agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for May 2029, 23 months later.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 23 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Aug 2026 → Jun 2027, primary completion Jul 2028 → May 2029 and completion Jan 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 13, 2026
StartEst.
Jun 1, 2027was Aug 2026
Primary completionEst.
May 31, 2029was Jul 2028
CompletionEst.
Dec 31, 2029was Jan 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Jun 1, 2027
Nov 13, 2026
Primary completion
Jul 31, 2028→May 31, 2029
Nov 13, 2026
Study completion
Jan 31, 2029→Dec 31, 2029
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Aug 1, 2026→Jun 1, 2027
    Primary completion Jul 31, 2028→May 31, 2029
    Study completion Jan 31, 2029→Dec 31, 2029
    + 3 other changes: verification date, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07526285
Collaborators
United States Air Force Research Laboratory
Responsible party
Kaloyan Tanev, MD (Chief Scientific Officer, Massachusetts General Hospital) — Principal investigator
First posted
Apr 13, 2026
Start date
Jun 1, 2027 (estimated)
Primary completion
May 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Joseph Bonvie, PsyD
Contact
jbonvie@mgh.harvard.edu
8572053407
Alan Berkeley, MBA
Contact
aberkeley@mgh.harvard.edu
8572839928
Kaloyan S Tanev, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion